This article is more than 5 years old. Information may no longer be current.
AdaptDx dark adaptation testing selected for large AMD study
Click Here to Manage Email Alerts
MacuLogix Inc. announced that AdaptDx has been selected as a functional testing device for candidate clinical endpoint development in the MACUSTAR project, a 5-year study exploring novel outcome measures for future interventional trials in patients with intermediate age-related macular degeneration.
The investigation is currently funded with more than 16 million euros from the European Innovative Medicines Initiative and will enroll 750 patients in seven countries across Europe, according to a press release from MacuLogix.
AdaptDx, the only commercially available automated dark adaptometer, will be used at all 20 MACUSTAR study sites.
AdaptDx works by measuring a patient’s rod intercept time, which is the number of minutes it takes for the eye to adapt from bright light to darkness.
Initial study results are expected to be announced in 2019, according to the release.
The research project will be conducted at 20 clinical study centers in Europe, including the University Eye Clinic Bonn and the GRADE Reading Center Bonn, the Moorfields Eye Hospital, the University College, the City University, the Fondation voir et entendre Paris, the Coimbra Association for Innovation and Biomedical Research on Light and Image, the Radound University Medical Center, the University of Sheffield and the European Clinical Research Infrastructures Network Paris, as well as the companies Bayer AG, Novartis Pharma AG, Carl Zeiss-Meditec and F. Hoffmann La-Roche.